Qualquer síndrome de Cushing causada pelo excesso prolongado de cortisol no corpo, que pode ou não depender do hormônio ACTH.
Introdução
O que você precisa saber de cara
Qualquer síndrome de Cushing causada pelo excesso prolongado de cortisol no corpo, que pode ou não depender do hormônio ACTH.
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 52 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 126 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
10 genes identificados com associação a esta condição.
May inhibit the adenylyl cyclase-stimulating activity of guanine nucleotide-binding protein G(s) subunit alpha which is produced from the same locus in a different open reading frame
Cell membraneCell projection, ruffle
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells. CDH23 is required for establishing and/or maintaining the proper organization of the stereocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early postnatal development. It is part of the functional network formed by USH1C, USH1G, CDH23 and MYO7A that mediates mechanotransduction in cochlear hair cells. Required for norma
Cell membrane
Usher syndrome 1D
USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness.
Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of polyubiquitin precursors as well as that of ubiquitinated proteins (PubMed:16214042, PubMed:34059922). Plays a role in the regulation of NF-kappa-B activation by TNF receptor superfamily via its interactions with RELA and TRAF2. May also play a regulatory role at postsynaptic sites. Plays an important role in cell cycle progression by deubiquitinating Aurora B/AURKB an
CytoplasmNucleusCell projection, cilium
Deafness, autosomal dominant, 85
A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA85 is characterized by progressive hearing loss, with onset in childhood or young adulthood.
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)
NucleusCytoplasmCell membrane
Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of ta
CytoplasmNucleusMitochondrionCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, microtubule organizing center, centrosomeChromosomeNucleus, nucleoplasm
Glucocorticoid resistance, generalized
An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.
Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop
CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome
Involved in transcriptional regulation and chromatin remodeling. Facilitates DNA replication in multiple cellular environments and is required for efficient replication of a subset of genomic loci. Binds to DNA tandem repeat sequences in both telomeres and euchromatin and in vitro binds DNA quadruplex structures. May help stabilizing G-rich regions into regular chromatin structures by remodeling G4 DNA and incorporating H3.3-containing nucleosomes. Catalytic component of the chromatin remodeling
NucleusChromosome, telomereNucleus, PML body
Alpha-thalassemia/impaired intellectual development syndrome, X-linked
A disorder characterized by severe psychomotor retardation, facial dysmorphism, urogenital abnormalities, and alpha-thalassemia. An essential phenotypic trait are hemoglobin H erythrocyte inclusions.
Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context (PubMed:15620353, PubMed:15811342, PubMed:16079794, PubMed:16079795, PubMed:16140033, PubMed:16223729, PubMed:27292636). Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed (PubMed:15620353, PubMed:15811342, PubMed:16079794, PubMed:21300290, PubMed:26214369). Acts as a c
NucleusChromosome
Cleft palate, psychomotor retardation, and distinctive facial features
A syndrome characterized by cleft palate, developmental delay, psychomotor retardation, and facial dysmorphic features including a prominent forehead, slightly arched eyebrows, elongated palpebral fissures, a wide nasal bridge, thin lips, and widely spaced teeth. Cleft palate is a congenital fissure of the soft and/or hard palate, due to faulty fusion.
Substrate-recognition component of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes (PubMed:39504960, PubMed:39667934). The BCR(ARMC5) complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the BCR(ARMC5) complex acts by mediating ubiquitination of Pol II subu
NucleusChromosomeCytoplasm
ACTH-independent macronodular adrenal hyperplasia 2
A form of macronodular adrenal hyperplasia characterized by multiple, bilateral, non-pigmented, benign, adrenocortical nodules. It results in excessive production of cortisol leading to ACTH-independent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.
Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates t
CytoplasmNucleusEndosome membraneCell membrane
Pituitary adenoma 4, ACTH-secreting
A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA4 results in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.
Variantes genéticas (ClinVar)
1,778 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
76 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Síndrome Cushing endógena
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
4 ensaios clínicos encontrados, 2 ativos.
Publicações mais relevantes
Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
Endogenous Cushing syndrome (CS) is a rare disorder resulting from chronic exposure to excessive concentrations of cortisol. It is likely underdiagnosed because many clinical signs and symptoms are non-specific and overlap with those of common conditions. Furthermore, biochemical testing to diagnose CS can be complex and challenging, especially in milder cases. CS is characterized by excessive daily cortisol production, but it is also associated with a disrupted circadian rhythm of cortisol secretion. Traditional cortisol monitoring techniques rely on single-time-point measurements or a cumulation of measurements, which are unable to capture the complete daily rhythm of cortisol fluctuations. Currently, the utility of assessing individual patients' cortisol circadian rhythm during diagnosis and treatment of CS is not well characterized. In this review we will discuss how cortisol is measured in clinical practice and the potential benefit of measurement and normalization of the cortisol circadian rhythm.
Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.
Endogenous Cushing syndrome is associated with an intrinsic hypercoagulable state and an increased risk of venous thromboembolism (VTE). This study aimed to determine the prevalence and risk factors for VTE in a large cohort of patients with Cushing disease (CD). A retrospective study was conducted at a tertiary care center, including 408 patients diagnosed with CD. Clinical, laboratory, hormonal, imaging, and outcome data were analyzed and compared based on the occurrence of VTE events. A control group of 323 patients with clinically nonfunctioning pituitary adenomas, all macroadenomas, who underwent similar surgical procedures, was used for comparison. VTE events were observed in 35 patients with CD (8.6%) and in 1 patient from the nonfunctioning pituitary adenoma group (0.3%; P < .001). The slight majority of VTE events (54%) occurred in the preoperative period. Logistic regression analysis identified obesity, mood disorders, supraclavicular fossa fullness, leukopenia or leukocytosis, elevated cortisol levels (both serum and 24-hour urinary cortisol), and the presence of postoperative complications (such as infections, cerebrospinal fluid leak, and vasopressin deficiency) as significant risk factors for VTE. The findings of this study confirm a high prevalence of VTE events in patients with CD, irrespective of the surgical period. Risk factors associated with a higher likelihood of VTE include obesity, severity of hypercortisolism, and the occurrence of postoperative complications. In this patient population, thromboprophylaxis should be considered.
Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.
Osilodrostat's clinical development program mostly enrolled Cushing disease patients. Data in non-pituitary Cushing syndrome (CS) are limited. Evaluate osilodrostat effectiveness and safety in non-pituitary CS in real-world practice in France. Retrospective, observational study (LINC 7; NCT05633953). Data for patients who initiated osilodrostat under the French Autorisation Temporaire d'Utilisation scheme or, once approved, in routine clinical practice were extracted retrospectively for ≤36 months (2019-2022). Multicenter institutional practice. 103 adult non-pituitary CS patients: ectopic adrenocorticotropic hormone secretion (EAS), n=53; adrenocortical carcinoma (ACC), n=19; adrenal adenoma (AA), n=17; bilateral adrenal nodular disease (BND), n=14. 43 remained on osilodrostat throughout the observation period. Median (min-max) osilodrostat exposure and baseline dose: 177 days (1-1178), 5.0 mg/day (1-60). Proportion with mean urinary free cortisol (mUFC) ≤ upper limit of normal (ULN) at week (W) 12 (modified intention-to-treat [mITT] population: all enrolled patients with ≥12W follow-up, excluding patients without W12 mUFC for non-safety reasons). Osilodrostat was initiated and titrated based on investigator judgment. Cortisol decreased by W4, remaining stable thereafter. 23/52 patients (mITT; 44.2%, 95% CI 30.5-58.7) had mUFC ≤ULN at W12 (missing values input as non-responders). 45/52 had W12 mUFC available; proportion with mUFC ≤ULN by etiology: EAS, n=12/29 (41%); ACC, n=4/6; AA, n=1/3; BND, n=6/7. Most common (≥15%) TEAEs: adrenal insufficiency (28%) and hypokalemia (18%). 29 patients (EAS, n=24; ACC, n=5) died from AEs (n=1 assessed as osilodrostat related by investigator), mostly neoplasm progression (n=11). Osilodrostat is a suitable treatment for endogenous Cushing syndrome of various non-pituitary etiologies.
Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.
Osilodrostat is a potent oral steroidogenesis inhibitor that is an effective medical therapy in the management of patients with endogenous Cushing syndrome. However, due to its high therapeutic potential, it is associated with a high risk of inducing adrenal insufficiency (AI). Recently, it has also been reported that patients may experience prolonged adrenal suppression during osilodrostat treatment that persists despite its withdrawal. In this paper, we present a male patient with persistent Cushing's disease (CD) who experienced several episodes of AI during long-term treatment with osilodrostat. Ultimately, due to the patient's very low dose of osilodrostat, it was decided to discontinue the therapy after 270 weeks in total. Following the cessation of osilodrostat, the patient commenced treatment with recombinant human growth hormone due to severe growth hormone deficiency, which revealed an underlying cortisol deficiency, likely caused by a prolonged adrenocortical blockage induced by osilodrostat, requiring the initiation of hydrocortisone replacement therapy. During and after the osilodrostat therapy, we additionally observed a low serum concentration of dehydroepiandrosterone sulfate (DHEA-S) despite elevated plasma adrenocorticotrophin. This finding suggested potential inhibition of adrenal steroidogenesis upstream of 11β-hydroxylase. A urine steroid profile performed 40 weeks after discontinuing osilodrostat showed reduced or borderline excretion of cortisol metabolites, as well as significantly decreased excretion of DHEA metabolites. Finally, 62 weeks after the last exposure to osilodrostat, the patient presented with clinical and biochemical features of relapse of hypercortisolemia, and osilodrostat was reintroduced. This case highlights the importance of close monitoring in patients treated with osilodrostat, as hypocortisolemia can arise suddenly and unexpectedly at any point during treatment, even in those on stable doses. Additionally, it indicates that osilodrostat has the potential to induce prolonged adrenal blockade, even after treatment has ceased. The unexpected persistence of adrenal suppression suggests unknown long-term effects of osilodrostat that require further investigation.
Artri King induced Cushing syndrome in an 82-year-old man.
An 82-year-old man with a history of hypertension, thyroid nodule, and parkinsonism on carbidopa/levodopa was referred for a sudden eruption of scattered purpuric macules. He noted fatigue, weakness, ankle swelling, abdominal fullness, headaches, lapses in memory, and dysphasia. On physical examination, he had thin and atrophied upper extremities and central obesity, as well as nonblanching red to purple macules on the lower abdomen and ecchymosis on bilateral arms. The patient denied the use of any corticosteroids. Lab workup showed an abnormally high post-dexamethasone cortisol level, which raised suspicion for Cushing syndrome. Further inquiry into the patient's medication and supplement history revealed that he was consuming Artri King, a supplement marketed for the treatment of joint pain and arthritis. Artri King can lead to numerous dermatological manifestations akin to endogenous Cushing syndrome such as thin skin, easy bruising, and purple striae. This case illustrates the potential risks of over-the-counter dietary supplements, which often circumvent the strict Food and Drug Administration regulations applied to prescription medications, posing significant health hazards to users. There is critical need for transparency and regulation of supplements.
Publicações recentes
"Glucocorticoids, Cushing syndrome and cellular senescence: a mechanistic link to metabolic ageing".
The Modern Presentation, Etiology, and Rate of Occurrence of Cushing Syndrome Differs when Compared to Prior Population-Based Studies.
Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.
Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.
📚 EuropePMC19 artigos no totalmostrando 55
Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
The Journal of clinical endocrinology and metabolismReal-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.
The Journal of clinical endocrinology and metabolismPrevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsProlonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.
Frontiers in medicineArtri King induced Cushing syndrome in an 82-year-old man.
Dermatology online journalAdvances in the medical management of hypercortisolism: current strategies, monitoring, and emerging therapies.
Current opinion in endocrinology, diabetes, and obesityCushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review.
DiabetesOsilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study.
Journal of the Endocrine SocietyOsilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations.
Journal of the Endocrine SocietyRelationship Among Fragility Fractures and the Overall Cardiovascular Burden in Endogenous Cushing Syndrome.
Journal of the Endocrine SocietyBone Mineral Density Improvement After Resolution of Endogenous Cushing Syndrome: A Systematic Review and Meta-Analysis.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsRelacorilant or surgery improved hemostatic markers in Cushing syndrome.
Journal of endocrinological investigationPaediatric Cushing syndrome: a prospective, multisite, observational cohort study.
The Lancet. Child & adolescent healthARMC5-negative primary bilateral macronodular adrenal hyperplasia.
BMJ case reportsCushing disease in pediatrics: an update.
Annals of pediatric endocrinology & metabolism[Dynamics of NT-proBNP and ST2 levels as markers of heart failure in patients with endogenous Cushing syndrome (hypercortisolism)].
Terapevticheskii arkhivApproach to the Patient: Diagnosis of Cushing Syndrome.
The Journal of clinical endocrinology and metabolismUltra-high field 7 T MRI localizes regional brain volume recovery following corticotroph adenoma resection and hormonal remission in Cushing's disease: A case series.
Surgical neurology internationalA Two-in-One Tumor in the Adrenal: A Functional Adrenocortical Adenoma with Myelolipomatous Differentiation.
Fetal and pediatric pathologyThe Effect of Endogenous Cushing Syndrome on All-cause and Cause-specific Mortality.
The Journal of clinical endocrinology and metabolismGlucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome.
PituitaryEpidemiology of Male Hypogonadism.
Endocrinology and metabolism clinics of North AmericaInflammatory biomarkers in the evaluation of pediatric endogenous Cushing syndrome.
European journal of endocrinologyRelacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Frontiers in endocrinologyCushing Syndrome Associated Myopathy: It Is Time for a Change.
Endocrinology and metabolism (Seoul, Korea)Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry.
The Journal of steroid biochemistry and molecular biologyCushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21.
The Journal of allergy and clinical immunologyTo determine the efficacy of bilateral inferior petrosal sinus sampling in differentiating Cushing disease from ectopic Cushing syndrome.
JPMA. The Journal of the Pakistan Medical AssociationClinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.
Clinical diabetes and endocrinologyAdrenally Directed Medical Therapies for Cushing Syndrome.
The Journal of clinical endocrinology and metabolismDifferences in outcomes of bilateral adrenalectomy in patients with ectopic ACTH producing tumor of known and unknown origin.
American journal of surgerySpinal Epidural Lipomatosis with Osteoporotic Vertebral Fractures Presenting as Acute Thoracic Myelopathy in a 33-Year-Old Man with Cushing Disease.
World neurosurgeryEctopic Cushing syndrome caused by a pancreatic neuroendocrine tumor: A case report.
Radiology case reportsPediatric Cushing Syndrome; an Overview.
Pediatric endocrinology reviews : PER68Ga-DOTATATE PET/CT of Ectopic Cushing Syndrome Due to Appendicular Carcinoid.
Clinical nuclear medicineHeat-Damaged Red Blood Cell Scintigraphy in Helping Interpretation of 68Ga-DOTATATE PET/CT.
Clinical nuclear medicineOptical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismeCarney Syndrome Presented as a Pathological Spine Fracture in a 35-Year-Old Male.
The American journal of case reportsMini-review of hair cortisol concentration for evaluation of Cushing syndrome.
Expert review of endocrinology & metabolismDiverticular Perforation: A Fatal Complication to Forestall in Cushing Syndrome.
The Journal of clinical endocrinology and metabolismIncidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismeCHOROIDAL THICKENING AND PACHYCHOROID IN CUSHING SYNDROME: Correlation With Endogenous Cortisol Level.
Retina (Philadelphia, Pa.)Evaluation of Evidence of Adrenal Insufficiency in Trials of Normocortisolemic Patients Treated With Mifepristone.
Journal of the Endocrine SocietyCirculatory Immune Cells in Cushing Syndrome: Bystanders or Active Contributors to Atherometabolic Injury? A Study of Adhesion and Activation of Cell Surface Markers.
International journal of endocrinologyHypercortisolemia and Depressive-like Behaviors in a Rhesus Macaque (Macaca mulatta) Involved in Visual Research.
Comparative medicineInfluence of age, gender and body mass index on late-night salivary cortisol in healthy adults.
Clinical chemistry and laboratory medicineCircadian Plasma Cortisol Measurements Reflect Severity of Hypercortisolemia in Children with Different Etiologies of Endogenous Cushing Syndrome.
Hormone research in paediatricsCushing syndrome in a child due to pro-opiomelanocortin (POMC) secretion from a yolk sac tumor.
European journal of endocrinologyEffects of Glucocorticoids on Bone: What we can Learn from Pediatric Endogenous Cushing's Syndrome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismeDiurnal Plasma Cortisol Measurements Utility in Differentiating Various Etiologies of Endogenous Cushing Syndrome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismeDiagnosis and Clinical Genetics of Cushing Syndrome in Pediatrics.
Endocrinology and metabolism clinics of North AmericaCases of Psychiatric Morbidity in Pediatric Patients After Remission of Cushing Syndrome.
Pediatrics[Serum Myokines Levels in Patients with Endogenous Cushing Syndrome and Acromegaly: Cross-Sectional Case−Control Study].
Vestnik Rossiiskoi akademii meditsinskikh naukKaposi sarcoma secondary to endogenous adrenocorticotropic hormone-dependent Cushing syndrome.
The British journal of dermatologyASSOCIATION BETWEEN MIFEPRISTONE DOSE, EFFICACY, AND TOLERABILITY IN PATIENTS WITH CUSHING SYNDROME.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Síndrome Cushing endógena.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Síndrome Cushing endógena
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement.
- Prevalence and Associated Risk Factors for Venous Thromboembolism in a Large Cohort of Patients With Cushing Disease.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists· 2026· PMID 41106685mais citado
- Real-world osilodrostat effectiveness and safety in non-pituitary Cushing syndrome.
- Prolonged adrenal suppression after osilodrostat discontinuation in a patient with Cushing's disease with eventual hypercortisolism relapse: Case Report and literature review.
- Artri King induced Cushing syndrome in an 82-year-old man.
- "Glucocorticoids, Cushing syndrome and cellular senescence: a mechanistic link to metabolic ageing".
- The Modern Presentation, Etiology, and Rate of Occurrence of Cushing Syndrome Differs when Compared to Prior Population-Based Studies.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:641613(Orphanet)
- MONDO:0957431(MONDO)
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
